Physician profile
Deborah Bykowski
NPI 1366883498
$2,685.26
in general payments reported to CMS, 2019-2025
19 companies · $692 in 2025
The $692 reported for 2025 was more than what 87% of Psychiatric/Mental Health, Adult (Registered Nurse) providers received nationally (typical 2025 total: $121).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.03 · 2022: $96.02 · 2023: $1,023 · 2024: $855 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,347 · Education: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,347.23 |
| Education | $222.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $487.95 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $414.52 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $329.41 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $257.03 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $203.26 | 2023-2025 | Auvelity, Sunosi |
| Ironshore Pharmaceuticals INC. | $177.21 | 2023 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $161.43 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $145.85 | 2021-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $125.26 | 2023 | Qelbree |
| Corium, LLC | $112.37 | 2023-2025 | Azstarys |
| Bausch Health US, LLC | $67.06 | 2023-2025 | Wellbutrin, Aplenzin |
| Vertical Pharmaceuticals, LLC | $35.96 | 2025 | Relexxii |
| Almatica Pharma LLC | $33.37 | 2023 | Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $28.30 | 2023-2024 | Rexulti |
| Avadel Cns Pharmaceuticals, LLC | $24.70 | 2024 | Lumryz |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $22.49 | 2025 | Zurzuvae |
| Neos Therapeutics, Lp | $22.31 | 2023 | Adzenys Xr-Odt |
| Janssen Pharmaceuticals, INC | $19.53 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.25 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Bykowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.